Evidence map›Paper›PMID 26885252›Full record

ArticleOxidative medicine and cellular longevity2016

Effect of Carnosine in Experimental Arthritis and on Primary Culture Chondrocytes.

S Ponist, F Drafi, V Kuncirova, D Mihalova, L Rackova, L Danisovic, O Ondrejickova, I Tumova, O Trunova, T Fedorova and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Carnosine and bone (Review).Molecular medicine reports · 2023
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Metabolites · 2020
    Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

S PonistInstitute of Experimental Pharmacology and Toxicology, Slovak Academy of Sciences, Dubravska cesta 9, 841 04 Bratislava, Slovakia.
F DrafiInstitute of Experimental Pharmacology and Toxicology, Slovak Academy of Sciences, Dubravska cesta 9, 841 04 Bratislava, Slovakia.
V KuncirovaInstitute of Experimental Pharmacology and Toxicology, Slovak Academy of Sciences, Dubravska cesta 9, 841 04 Bratislava, Slovakia.
D MihalovaInstitute of Experimental Pharmacology and Toxicology, Slovak Academy of Sciences, Dubravska cesta 9, 841 04 Bratislava, Slovakia.
L RackovaInstitute of Experimental Pharmacology and Toxicology, Slovak Academy of Sciences, Dubravska cesta 9, 841 04 Bratislava, Slovakia.
L DanisovicFaculty of Medicine, Comenius University in Bratislava, Spitalska 24, 813 72 Bratislava, Slovakia.
O OndrejickovaInstitute of Experimental Pharmacology and Toxicology, Slovak Academy of Sciences, Dubravska cesta 9, 841 04 Bratislava, Slovakia.
I TumovaFaculty of Pharmacy, Comenius University in Bratislava, Odbojarov 10, 832 32 Bratislava, Slovakia.
O TrunovaResearch Center of Neurology, RAMS, Volokolamskoyeshosse 80, Moscow 125367, Russia.
T FedorovaResearch Center of Neurology, RAMS, Volokolamskoyeshosse 80, Moscow 125367, Russia.
K BauerovaInstitute of Experimental Pharmacology and Toxicology, Slovak Academy of Sciences, Dubravska cesta 9, 841 04 Bratislava, Slovakia; Faculty of Pharmacy, Comenius University in Bratislava, Odbojarov 10, 832 32 Bratislava, Slovakia.
Slovak Academy of Sciences · SKInstitute of Experimental Pharmacology and Toxicology of the Slovak Academy of Sciences · SKComenius University Bratislava · SKResearch Center of Neurology · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carnosine's (CARN) anti-inflammatory potential in autoimmune diseases has been but scarcely investigated as yet. The aim of this study was to evaluate the therapeutic potential of CARN in rat adjuvant arthritis, in the model of carrageenan induced hind paw edema (CARA), and also in primary culture of chondrocytes under H2O2 injury. The experiments were done on healthy animals, arthritic animals, and arthritic animals with oral administration of CARN in a daily dose of 150 mg/kg b.w. during 28 days as well as animals with CARA treated by a single administration of CARN in the same dose. CARN beneficially affected hind paw volume and changes in body weight on day 14 and reduced hind paw swelling in CARA. Markers of oxidative stress in plasma and brain (malondialdehyde, 4-hydroxynonenal, protein carbonyls, and lag time of lipid peroxidation) and also activity of gamma-glutamyltransferase were significantly corrected by CARN. CARN also reduced IL-1alpha in plasma. Suppression of intracellular oxidant levels was also observed in chondrocytes pretreated with CARN. Our results obtained on two animal models showed that CARN has systemic anti-inflammatory activity and protected rat brain and chondrocytes from oxidative stress. This finding suggests that CARN might be beneficial for treatment of arthritic diseases.

Indexed as

Adjuvants, ImmunologicAldehydesAnimalsArthritis, ExperimentalBody WeightCarnosineCarrageenanCells, CulturedCell SurvivalChondrocytesEdemaHydrogen PeroxideInterleukin-1alphaIntracellular SpaceLuminescent MeasurementsMale4-hydroxy-2-nonenalAdjuvants, ImmunologicAldehydesCarnosineCarrageenanHydrogen PeroxideInterleukin-1alphaMalondialdehyde

Identifiers

PMID26885252
PMCPMC4739233
OpenAlexW2261684505

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.